-- Singapore Joins Marken's Other Facilities around the Globe
RESEARCH TRIANGLE PARK, North Carolina, Aug. 8, 2013 /PRNewswire/ -- Marken announced today that they have expanded their kit-building operations into Singapore due to a growing demand from its clients. The facility is fully operational and began shipping for its first client earlier this year.
The kit-building unit in Singapore is managed by a dedicated trained staff and is supported by the GMP operators and QA personnel who operate the depot facility. The depot / kit facility is also adjacent to Marken's Singapore distribution hub, located near the Chiangi airport. Marken staff can therefore receive drug product and kit materials at the depot, assemble and store kits, store drug product and distribute all clinical materials to investigator sites throughout Asia.
The addition of the Singapore site is part of an ongoing global expansion plan within Marken. With kit-building locations already operational in Hamburg and now Singapore, Marken is also evaluating an additional kit-building facility in either Miami or Brazil in the coming months.
Marken currently produces 15,000 kits per month and distributes more than 350,000 kits annually to investigator sites around the world. Ample capacity is currently available, and more capacity will be added as client demand develops.
Wes Wheeler, Marken's Chief Executive Officer, said, "We are pleased to be able to offer this expanded service to our clients in the APAC region. Our ability to assemble kits in Singapore gives us a solid platform in Asia and again enhances our portfolio of services to clients in the region. We look forward to serving more global clients with our other facilities as we continue to grow, both in the Asia region and around the world."
Marken is the leading global clinical supply chain solutions provider dedicated to the pharmaceutical and life sciences industries, supporting over 49,000 clinical investigators in more than 150 countries. Marken integrates Depot and Logistics services into solutions that extend the reach of clinical trials to even the most remote treatment naive geographies.